Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma

Potent antiviral therapy (AVT) against hepatitis B virus (HBV) can induce regression of liver fibrosis, thereby reducing the development of liver cirrhosis and hepatocellular carcinoma (HCC) [1]. A high recurrence rate even after curative surgical resection of HCC remains a major challenge [2].